Source-grounded facts extracted from ABBOTT LABORATORIES's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ABBOTT LABORATORIES: Board size increased from twelve to thirteen directors (effective 2026-04-24).
“On April 24, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective April 24, 2026.”
ABBOTT LABORATORIES updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.”
ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.
“On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes”
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
“The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.”
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
“On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes”
ABBOTT LABORATORIES: Board reduced from thirteen to twelve members, effective April 24, 2026 (effective 2026-04-24).
“On February 20, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s By-Laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective April 24, 2026.”
ABBOTT LABORATORIES: Increased board size from twelve to thirteen directors by amending Article III, Section 2 of the by-laws (effective 2025-12-12).
“On December 12, 2025, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective as of December 12, 2025.”
Hubert L. Allen departed as Executive Vice President, General Counsel and Secretary at ABBOTT LABORATORIES.
“On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.”
Robert E. Funck, Jr. departed as Executive Vice President, Finance at ABBOTT LABORATORIES.
“Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.